Nyxoah S.A.
NYXH
$-0.15
Change (1 day)
$20.00
Year High
$4.00
Year Low
Categories
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. (NYXH) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 2.76 M | -8,906,000 | 26.14 M | 124.16 M | 68.35 M |
| 2022 | 1.78 M | -6,006,000 | 25.75 M | 146.07 M | 100.26 M |
| 2021 | 2.51 M | -123,834,000 | 22.21 M | 170.83 M | 140.06 M |
| 2020 | 1.64 M | -80,760,000 | 16.89 M | 114.08 M | 94.11 M |
| 2019 | 2.11 M | 2.74 M | 11.48 M | 15.2 M | 7.97 M |